

Cecily J Forsyth

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6753972/publications.pdf>

Version: 2024-02-01

31
papers

345
citations

1040056

9
h-index

839539

18
g-index

32
all docs

32
docs citations

32
times ranked

626
citing authors

#	ARTICLE	IF	CITATIONS
1	Proteasome inhibitor-induced coronary vasospasm in multiple myeloma: a case report. <i>European Heart Journal - Case Reports</i> , 2021, 5, ytab076.	0.6	3
2	Subacute combined degeneration of the spinal cord due to pernicious anaemia with an erroneously normal active <sc>B12</sc> level. <i>Internal Medicine Journal</i> , 2021, 51, 1184-1185.	0.8	1
3	115â€¦Erroneously normal active B12 level in a case of subacute combined degeneration of the cord. , 2021, , .		0
4	Variation in Use of Immunoglobulin and Impact on Survival in Multiple Myeloma: A Report from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR). <i>Blood</i> , 2021, 138, 4757-4757.	1.4	0
5	Variable incidence of myeloproliferative neoplasms in Australia. <i>Internal Medicine Journal</i> , 2021, 51, 1979-1980.	0.8	0
6	Non-anaemic iron deficiency. <i>Australian Prescriber</i> , 2021, 44, 193-196.	1.0	15
7	Outpatient rituximab, ifosfamide, etoposide (R-IE) in patients older than 60 years with relapsed or refractory diffuse large B-cell lymphoma who are not candidates for stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2020, 61, 91-97.	1.3	6
8	Efficacy and Safety of ABP 798: Results from the JASMINE Trial in Patients with Follicular Lymphoma in Comparison with Rituximab Reference Product. <i>Targeted Oncology</i> , 2020, 15, 599-611.	3.6	12
9	RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML. <i>Blood Advances</i> , 2020, 4, 1131-1144.	5.2	102
10	Cutaneous multiple myeloma. <i>British Journal of Haematology</i> , 2020, 190, 134-134.	2.5	1
11	Long-Term Outcomes and Health-Related Quality of Life (HRQoL) By Response Status for Bortezomib, Melphalan, and Prednisone (VMP) ± Daratumumab (DARA) in Alcyone. <i>Blood</i> , 2020, 136, 43-44.	1.4	1
12	Efficacy and safety of ABP 798 compared with rituximab: Results from the comparative clinical study in patients with non-Hodgkinâ€™s. <i>Journal of Clinical Oncology</i> , 2020, 38, 8044-8044.	1.6	0
13	Totality of Scientific Evidence in the Development of ABP 798, a Biosimilar to Rituximab. <i>Blood</i> , 2020, 136, 35-36.	1.4	0
14	Changing incidence of myeloproliferative neoplasms in Australia, 2003â€”2014. <i>American Journal of Hematology</i> , 2019, 94, E107-E109.	4.1	16
15	The natural history of vascular and other complications in patients treated with nilotinib for chronic myeloid leukemia. <i>Blood Advances</i> , 2019, 3, 1084-1091.	5.2	17
16	Recommendations for the use of pegylated interferonâ€” in the treatment of classical myeloproliferative neoplasms. <i>Internal Medicine Journal</i> , 2019, 49, 948-954.	0.8	7
17	Delayedâ€”onset heparinâ€”induced thrombocytopenia complicated by arterial and venous thromboses. <i>Internal Medicine Journal</i> , 2018, 48, 98-100.	0.8	3
18	The delayed diagnosis of myeloproliferative neoplasms is common and results in a high incidence of potentially preventable thrombotic complications. <i>Pathology</i> , 2018, 50, 775-776.	0.6	6

#	ARTICLE	IF	CITATIONS
19	Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study. <i>British Journal of Haematology</i> , 2017, 177, 441-448.	2.5	21
20	The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia. <i>Blood Advances</i> , 2017, 1, 802-811.	5.2	31
21	Raccoon eyes in systemic light chain amyloidosis. <i>Medical Journal of Australia</i> , 2017, 206, 384-384.	1.7	1
22	Upfront Imatinib with Selective Early Switching to Nilotinib Leads to Excellent Achievement of Deep Molecular Response in Chronic Phase CML: 5 Year (Final) Analysis of the TIDEL-II Study. <i>Blood</i> , 2016, 128, 939-939.	1.4	0
23	TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets. <i>Blood</i> , 2015, 125, 915-923.	1.4	77
24	Quality of Life in Fit Elderly Patients with Chronic Lymphocytic Leukemia (CLL) Receiving Oral Fludarabine-Based Regimens As First Line Therapy: Australasian Leukaemia and Lymphoma Group (ALLG) CLL5 Trial. <i>Blood</i> , 2015, 126, 5295-5295.	1.4	0
25	A Randomised Dose De-Escalation Study of Oral Fludarabine, ±Oral Cyclophosphamide and Intravenous Rituximab As First-Line Therapy of Fit Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years: Final Analysis of Response and Toxicity. <i>Blood</i> , 2014, 124, 3325-3325.	1.4	13
26	Toxicity Is Not Associated with Age or Comorbidity Score in a Randomised Study of Oral Fludarabine and Cyclophosphamide and IV Rituximab (FCR) As First-Line Therapy of Fit, Elderly Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2014, 124, 4695-4695.	1.4	5
27	Early Dose-Escalation in Chronic Myeloid Leukaemia Patients with Low Plasma Imatinib Levels Leads to Equivalent BCR-ABL Values and Drug Levels at 6 Months to Those with Optimal Drug Levels: First Analysis From the TIDEL II Trial of De-Novo Patients Treated with 600mg Imatinib. <i>Blood</i> , 2009, 114, 1131-1131.	1.4	4
28	Enzastaurin in Patients with Non-Hodgkin Lymphomas: A Multicenter, Open-Label, Screening Study. <i>Blood</i> , 2009, 114, 3719-3719.	1.4	2
29	Immunoglobulin G (IgG) Subclasses in Chronic Lymphocytic Leukaemia. <i>Blood</i> , 2008, 112, 4180-4180.	1.4	0
30	FDG PET-CT in Primary Staging and Management of Hodgkin Lymphoma (HL) and Non-Hodgkin Lymphoma (NHL): Experience in 465 Consecutive Patients. <i>Blood</i> , 2006, 108, 2398-2398.	1.4	0
31	Paraprotein associated heparin resistance during cardiopulmonary bypass. <i>Perfusion (United Tj ETQq1 1 0.784314,rgBT /Overlock 10</i>	1.8	0